Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas

International Journal of Cancer

Volumn 125, Issue 4, 2009, Pages 807-815

  Wang, Chien Kai ^a   Chang, Han ^b   Chen, Po Hung ^a,b   Chang, Jinghua Tsai ^b   Kuo, Yu Chun ^a   Ko, Jiunn Liang ^b   Lin, Pinpin ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Aryl hydrocarbon receptor; Fibroblast growth factor 9; Lung adenocarcinoma

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; FIBROBLAST GROWTH FACTOR 9;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER GROWTH; CELL COMMUNICATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL COMMUNICATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 9; FIBROBLASTS; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTORS, ARYL HYDROCARBON; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 67650065531     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24348     Document Type: Article

References (51)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Wakelee HA, Chang ET, Gomez SL, Keegan TH, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, West DW. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-8.
3. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006;11:533-8.
4. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev 2007;7:139-47.
5. Ueng TH, Hu SH, Chen RM, Wang HW, Kuo ML. Induction of cytochrome P-450 1A1 in human hepatoma HepG2 and lung carcinoma NCI-H322 cells by motorcycle exhaust particulate. J Toxicol Environ Health A 2000;60:101-19.
6. Chiang TA, Wu PF, Ko YC. Identification of carcinogens in cooking oil fumes. Environ Res 1999;81:18-22.
7. Risner CH. The determination of benzo[a]pyrene in the total particulate matter of cigarette smoke. J Chromatogr Sci 1988;26:113-20.
8. Ueng TH, Hung CC, Kuo ML, Chan PK, Hu SH, Yang PC, Chang LW. Induction of fibroblast growth factor-9 and interleukin-1alpha gene expression by motorcycle exhaust particulate extracts and benzo(a)pyrene in human lung adenocarcinoma cells. Toxicol Sci 2005;87:483-96.
9. Pogach MS, Cao Y, Millien G, Ramirez MI, Williams MC. Key developmental regulators change during hyperoxia-induced injury and recovery in adult mouse lung. J Cell Biochem 2007;100:1415-29.
10. Colvin JS, White AC, Pratt SJ, Ornitz DM. Lung hypoplasia and neonatal death in Fgf9-null mice identify this gene as an essential regulator of lung mesenchyme. Development 2001;128:2095-106.
11. Jin C, Wang F, Wu X, Yu C, Luo Y, McKeehan WL. Directionally specific paracrine communication mediated by epithelial FGF9 to stromal FGFR3 in two-compartment premalignant prostate tumors. Cancer Res 2004;64:4555-62.
12. Hendrix ND, Wu R, Kuick R, Schwartz DR, Fearon ER, Cho KR. Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res 2006;66:1354-62.
13. Shimizu Y, Nakatsuru Y, Ichinose M, Takahashi Y, Kume H, Mimura J, Fujii-Kuriyama Y, Ishikawa T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 2000;97:779-82.
14. Chang JT, Chang H, Chen PH, Lin SL, Lin P. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007;13:38-45.
15. Whitlock JP Jr. Induction of cytochrome P4501A1. Annu Rev. Pharmacol Toxicol 1999;39:103-25.
16. Zhang L, Shiverick KT. Benzo(a)pyrene, but not 2,3,7,8- tetrachlorodibenzo-p-dioxin, alters cell proliferation and c-myc and growth factor expression in human placental choriocarcinoma JEG-3 cells. Biochem Biophys Res Commun 1997;231:117-20.
17. Chen TM, Kuo PL, Hsu CH, Tsai SJ, Chen MJ, Lin CW, Sun HS. Microsatellite in the 3′ untranslated region of human fibroblast growth factor 9 (FGF9) gene exhibits pleiotropic effect on modulating FGF9 protein expression. Hum Mutat 2007;28:98.
18. Hu SW, Chen CC, Kuo CY, Lin WH, Lin P. Increased cytochrome P4501B1 gene expression in peripheral leukocytes of municipal waste incinerator workers. Toxicol Lett 2006;160:112-20.
19. Lin P, Chang H, Ho WL, Wu MH, Su JM. Association of aryl hydrocarbon receptor and cytochrome P4501B1 expressions in human nonsmall cell lung cancers. Lung Cancer (Amsterdam, Netherlands) 2003;42:255-61.
20. Agrotis A, Kanellakis P, Kostolias G, Di Vitto G, Wei C, Hannan R, Jennings G, Bobik A. Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. J Biol Chem 2004;279:42221-9.
21. del Moral PM, De Langhe SP, Sala FG, Veltmaat JM, Tefft D, Wang K, Warburton D, Bellusci S. Differential role of FGF9 on epithelium and mesenchyme in mouse embryonic lung. Dev Biol 2006;293:77-89.
22. Chang JT. An economic and efficient method of RNAi vector constructions. Anal Biochem 2004;334:199-200.
23. Abdelrahim M, Smith R, 3rd, Safe S. Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol Pharmacol 2003;63:1373-81.
24. Hestermann EV, Stegeman JJ, Hahn ME. Relative contributions of af-finity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency. Toxicol Appl Pharmacol 2000;168:160-72.
25. Kress S, Greenlee WF. Cell-specific regulation of human CYP1A1 and CYP1B1 genes. Cancer Res 1997;57:1264-9.
26. Safe SH. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol 1994;24:87-149.
27. Tsuchiya Y, Nakajima M, Yokoi T. Critical enhancer region to which AhR/ARNT and Sp1 bind in the human CYP1B1 gene. J Biochem (Tokyo) 2003;133:583-92.
28. Kitamura M, Kasai A. Cigarette smoke as a trigger for the dioxin receptor-mediated signaling pathway. Cancer Lett 2007;252:184-94.
29. Kasai A, Hiramatsu N, Hayakawa K, Yao J, Maeda S, Kitamura M. High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 2006;66:7143-50.
30. Brake PB, Jefcoate CR. Regulation of cytochrome P4501B1 in cultured rat adrenocortical cells by cyclic adenosine 3′,5′-monophosphate and 2,3,7,8-tetrachlorodibenzo-p-dioxin. Endocrinology 1995; 136:5034-41.
31. Zheng W, Jefcoate CR. Steroidogenic factor-1 interacts with cAMP response element-binding protein to mediate cAMP stimulation of CYP1B1 via a far upstream enhancer. Mol Pharmacol 2005;67:499-512.
32. Oesch-Bartlomowicz B, Huelster A, Wiss O, Antoniou-Lipfert P, Dietrich C, Arand M, Weiss C, Bockamp E, Oesch F. Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc Natl Acad Sci USA 2005;102:9218-23.
33. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001; 2:3005. Reviews.
34. Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16:139-49.
35. Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996;271:15292-7.
36. Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BL. Fibroblast growth factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung. Development 1997;124:4867-78.
37. Rowlands JC, Gustafsson JA. Aryl hydrocarbon receptor-mediated signal transduction. Crit Rev Toxicol 1997;27:109-34.
38. Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 1992;41:856-64.
39. Koliopanos A, Kleeff J, Xiao Y, Safe S, Zimmermann A, Buchler MW, Friess H. Increased arylhydrocarbon receptor expression offers a potential therapeutic target for pancreatic cancer. Oncogene 2002; 21:6059-70.
40. McDougal A, Wormke M, Calvin J, Safe S. Tamoxifen-induced antitumorigenic/antiestrogenic action synergized by a selective aryl hydrocarbon receptor modulator. Cancer Res 2001;61:3902-7.
41. Castro-Rivera E, Wormke M, Safe S. Estrogen and aryl hydrocarbon responsiveness of ECC-1 endometrial cancer cells. Mol Cell Endocrinol 1999;150:11-21.
42. Rowlands C, Krishnan V, Wang X, Santostefano M, Safe S, Miller WR, Langdon S. Characterization of the aryl hydrocarbon receptor and aryl hydrocarbon responsiveness in human ovarian carcinoma cell lines. Cancer Res 1993;53:1802-7.
43. Khan S, Barhoumi R, Burghardt R, Liu S, Kim K, Safe S. Molecular mechanism of inhibitory aryl hydrocarbon receptor-estrogen receptor/ Sp1 cross talk in breast cancer cells. Mol Endocrinol 2006;20:2199-214.
44. Barnes-Ellerbe S, Knudsen KE, Puga A. 2,3,7,8-Tetrachlorodibenzop-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol 2004; 66:502-11.
45. Jana NR, Sarkar S, Ishizuka M, Yonemoto J, Tohyama C, Sone H. Cross-talk between 2,3,7,8-tetrachlorodibenzo-p-dioxin and testosterone signal transduction pathways in LNCaP prostate cancer cells. Biochem Biophys Res Commun 1999;256:462-8.
46. Morrow D, Qin C, Smith R, 3rd, Safe S. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J Steroid Biochem Mol Biol 2004;88:27-36.
47. Wang WL, Porter W, Burghardt R, Safe SH. Mechanism of inhibition of MDA-MB-468 breast cancer cell growth by 2,3,7,8-tetrachlorodibenzo- p-dioxin. Carcinogenesis 1997;18:925-33.
48. Tamura K, Fukuoka M. Gefitinib in non-small cell lung cancer. Expert Opin Pharmacother 2005;6:985-93.
49. Felip E, Santarpia M, Rosell R. Emerging drugs for non-small-cell lung cancer. Expert Opin Emerg Drugs 2007;12:449-60.
50. Ezzat S, Zheng L, Winer D, Asa SL. Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. Mol Endocrinol 2006;20:2965-75.
51. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S. Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 2005;146:1145-53.